Home » Newsletters » BioWorld Science

BioWorld Science

March 26, 2012

View Archived Issues

New Wnt/catenin beta signaling inhibitor shows potential as cancer therapy

Durable submental fat reduction seen with ATX-101

Novel mTOR inhibitors reported

Merck KGaA develops novel inhibitors of tyrosine-protein kinases

GSK discloses new chemokine CCR4 receptor antagonists

U.S. university presents new vaccines for dengue

Peptide vaccine to enter phase IIa study

Hyperion Therapeutics acquires rights to Ravicti

Bioabsorbable stent shows promise in patients with coronary artery disease

Toray evaluates 11-beta-HSD1 inhibitor in obesity and diabetes models

New product extends therapeutic window of t-PA in stroke model

Coronado Biosciences signs agreement with Dr. Falk Pharma and OvaMed

GSK and Theravance complete registrational program

Byetta obtains European approval as add-on therapy to basal insulin

Medgenics receives clearance for phase IIa study in patients on dialysis

Mitsubishi Tanabe revises prescribing information for Imusera

NeuroDiscovery provides company update

Applications submitted for once-monthly risedronate sodium hydrate in Japan

Novel FLAP and leukotriene synthesis inhibitors patented

NeoPharm presents new protease-activated PAR2 receptor antagonists

Bionomics clear to initiate phase I/II trial of BNC-105

Kyorin Pharmaceutical reports novel AMPK activators

Pivotal LEAP trial reaches target enrollment

Endocyte receives approval for nonproprietary names of anticancer drug and companion imaging agent

EMA validates Raptor's MAA for RP-103

EMA to review Vivus' MAA for avanafil in ED

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...